Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 13, 2022

Smoking History and Overall Survival in Patients Receiving First-Line Pembrolizumab for Advanced NSCLC

JAMA Network Open


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Network Open
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
JAMA Netw Open 2022 May 02;5(5)e2214046, S Popat, SV Liu, N Scheuer, A Gupta, GG Hsu, SV Ramagopalan, F Griesinger, V Subbiah

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading